BGM Group Ltd. (BGM) Financial Ratio Screen

NASDAQ Healthcare China USD 94M
INSUFFICIENT / NOT IMPLEMENTED*
Automated financial screen · activity assessed separately
BGM Group Ltd. (BGM) needs additional financial data before the automated screen can be completed. One or more financial fields are missing; this is not a negative screening result.

Track BGM screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

BGM financial screening at a glance

INSUFFICIENT / NOT IMPLEMENTED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
0.0%
Pass vs 30%
Cash ratio
34.2%
Fail vs 30%
Receivables + cash
45.1%
Fail vs 30%
Impermissible income
N/A
Not available vs 5%

Calculation date: 2026-08-31. Financial period used: September 2024. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleMore financial data neededNo negative conclusion follows from missing data
FTSE/Yasaar-styleMore financial data neededNo negative conclusion follows from missing data
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodSeptember 2024Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Drug Manufacturers - Specialty & Generic) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from September 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 0.0%
/ 30%
34.2%
/ 30%
45.1%
/ 30%
N/A INSUFFICIENT / NOT IMPLEMENTED*
FTSE 0.0%
/ 33%
34.2%
/ 33%
45.1%
/ 50%
N/A INSUFFICIENT / NOT IMPLEMENTED*

Financial Highlights

EPS
$-0.29
P/B Ratio
0.3
EV/EBITDA
-29.1
EV: $69M
Revenue
$25M
Growth: -56.9%
Beta
1.5
High volatility
Current Ratio
7.0

Profitability

Gross Margin 2.9%
Operating Margin -5.4%
Net Margin -26.3%
Return on Equity (ROE) -16.5%
Return on Assets (ROA) -3.8%

Cash Flow & Balance Sheet

Operating Cash Flow$544,238
Free Cash Flow-$3M
Total Debt$0
Debt-to-Equity0.2
Current Ratio7.0
Total Assets$53M

Price & Trading

Last Close$0.52
50-Day MA$1.64
200-Day MA$6.81
Avg Volume51K
Beta1.5
52-Week Range
$0.45
$17.17

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-03-29 for the financial period September 2024. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About BGM Group Ltd. (BGM)

CEO
Mr. Chen Xin
Employees
298
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
China
Exchange
NASDAQ
Market Cap (listing currency)
USD 94M
Currency
USD

BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is BGM Group Ltd. (BGM) halal to invest in?

The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is BGM Group Ltd.'s debt ratio?

BGM Group Ltd.'s debt ratio is 0.0% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are BGM Group Ltd.'s key financial metrics?

BGM Group Ltd. has a market capitalization of USD 94M in its listing currency, and revenue of $25M. The company maintains a gross margin of 2.9% and a net margin of -26.3%. Return on equity stands at -16.5%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: September 2024. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.